MALT Lymphoma prognosis (MALT-IPI)
Estimate prognosis in MALT lymphoma
About
The MALT-IPI prognostic index was developed using a database of patients treated in an international randomized trial IELSG-19 (n=401) treated with chlorambucil, rituximab, or both. The index was subsequently validated by merging three independent cohorts of MALT lymphoma patients (including 633 patients).
The score is based on 3 simple clinical parameters that were able to discriminate patient prognosis into 3 risk groups (low, intermediate, and high) predictive for event-free and overall survival. The score was also able to discriminate prognosis for patients with gastric or non-gastric MALT lymphoma.
References
By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.